New trial aims to stop thymic cancer return with Chemo-Radiation combo

NCT ID NCT06402708

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding chemotherapy to standard radiation after thymic cancer surgery can prevent the cancer from coming back. About 172 adults who had complete tumor removal will receive either radiation alone or radiation plus four cycles of chemotherapy (paclitaxel, cisplatin, 5-FU). Researchers will track how long participants stay cancer-free and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (paclitaxel, cisplatin, 5-FU, calcium folinate) plus radiotherapy
What this could lead to: If it works, this could show that adding chemotherapy after surgery helps prevent thymic cancer from coming back.
What could go wrong: This is a mid-stage trial with only 172 people, so results may not apply to everyone. Chemotherapy can cause side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMIC CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 212013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.